Physician profile
Amanda H Champlain
NPI 1003180993
$11,301.49
in general payments reported to CMS, 2019-2025
32 companies · $3,184 in 2025
The $3,184 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $614 · 2021: $1,065 · 2022: $445 · 2023: $2,800 · 2024: $3,020 · 2025: $3,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,903 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,903.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,013.76 | 2020-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $1,228.66 | 2020-2025 | |
| Lilly USA, LLC | $831.06 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $698.75 | 2020-2025 | |
| Galderma Laboratories, L.P. | $646.84 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $592.77 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $570.32 | 2020-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $519.12 | 2020-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $415.23 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $388.71 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Leo Pharma INC. | $387.73 | 2021-2025 | Adbry, Anzupgo |
| Allergan, INC. | $377.36 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $301.12 | 2022-2024 | Sotyktu |
| Amgen INC. | $282.86 | 2020-2024 | Otezla |
| Ucb, INC. | $235.96 | 2020-2025 | Bimzelx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $137.79 | 2023-2025 | Opzelura |
| Revance Therapeutics, INC. | $108.25 | 2025 | Daxxify |
| Pfizer INC. | $76.53 | 2023-2025 | |
| Almirall LLC | $67.67 | 2022-2025 | Klisyri, Seysara |
| Organon LLC | $66.80 | 2025 | Nexplanon, Vtama |
| Journey Medical Corporation | $65.31 | 2022-2025 | |
| Genentech USA, INC. | $56.17 | 2025 | Xolair |
| Botanix Sb INC | $48.23 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $32.23 | 2020-2023 | |
| Fidia Pharma USA INC. | $22.21 | 2025 | |
| Sientra, INC. | $21.45 | 2022 | |
| Biofrontera INC. | $21.19 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $19.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.74 | 2024 | Cyltezo |
| Dermavant Sciences, INC. | $17.40 | 2024 | Vtama |
| Stemline Therapeutics INC. | $15.31 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Champlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.